Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

BACKGROUND: Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear. METHODS: Clinical and genomic data of 579 metastatic breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Juan, Li, Bin, Cao, Jianing, Li, Ting, Zhang, Jian, Cao, Jun, Zhao, Mingchuan, Wang, Leiping, Wang, Biyun, Tao, Zhonghua, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236705/
https://www.ncbi.nlm.nih.gov/pubmed/37264417
http://dx.doi.org/10.1186/s12967-023-04076-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236705/
https://www.ncbi.nlm.nih.gov/pubmed/37264417
http://dx.doi.org/10.1186/s12967-023-04076-9

Ejemplares similares